Author:
Schmitz-Dräger B. J.,Jankevicius F.,Ackermann R.
Publisher
Springer Berlin Heidelberg
Reference185 articles.
1. Abbolito A, Amoroso G, Gertoma R (1992) Epirubicin plus interferon versus interferon plus epirubicin in superficial bladder cancer. In: Guiliani L, Puppo P (eds) Urology. Monduzzi Editore, Bologna, pp 449–453
2. Ackermann D, Biedermann C, Baily G, Studer U (1988) Behandlung oberflächlicher Blasentumoren mit rIFN-aA-Installation (Roferon A): eine Phase I und II Studie. In: Ackermann R (ed) Verhandlungsbericht der Deutschen Gesellschaft für Urologie. Springer, Berlin Heidelberg New York, pp 211–212
3. Antonelli G, Gianelli G, Pistello M et al (1994) Clinical significance of recombinant interferon-alpha neutralizing antibodies in hepatitis patients. J Interferon Res 14: 211–213
4. Antonelli G, Currenti M, Turriziani O, Dianzani F (1991) Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis 163: 882–885
5. Atkins MB, Sprano J, Fisher RI et al (1993) Randomized phase II trial of high-dose interlenkin-2 either alone or in combination with interferon alpha-2b in advanced renal cell carcinoma. J Clin Oncol 11: 661–670